Search Results - "Zaucha, J. M."

Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL—a report from the EBMT registry by Sadowska-Klasa, A., Zaucha, J. M., Labopin, M., Bourhis, J. H., Blaise, D., Yakoub-Agha, I., Salmenniemi, U., Passweg, J., Fegueux, N., Schroeder, T., Giebel, S., Brissot, E., Ciceri, F., Mohty, M.

“…Secondary acute lymphoblastic leukemia (s-ALL) comprises up to 10% of ALL patients. However, data regarding s-ALL outcomes is limited. To answer what is the…”
Get full text

Imatinib therapy prior to myeloablative allogeneic stem cell transplantation by ZAUCHA, J. M, PREJZNER, W, HELLMANN, A, GIEBEL, S, GOOLEY, T. A, SZATKOWSKI, D, KALWAK, K, WOJNAR, J, KRUZEL, T, BALON, J, HOLOWIECKI, J

“…It is unknown whether imatinib prior to myeloablative haematopoietic stem cell transplantation (HSCT) increases transplant-related toxicity. Among the side…”
Get full text

Cold‐induced urticaria‐like lesions related to NLRP‐12 mutation by Cichoń, M., Zielińska, P., Zaucha, J. M., Zarzycka, E., Trzeciak, M.

Get full text

Prevention of hepatitis B virus transmission from an infected stem cell donor by Piekarska, A, Zaucha, J M, Hellmann, A, McDonald, G B

Get full text

Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant by STORB, R, CONG YU, ZAUCHA, J. M, DEEG, H. J, GEORGES, G, KIEM, H.-P, NASH, R. A, MCSWEENEY, P. A, WAGNER, J. L

“…Stable mixed chimerism can be established in dogs given a sublethal dose of 200 cGy total body irradiation (TBI) before and immunosuppression with…”
Get full text

THE LOW‐RISK EARLY‐STAGE HODGKIN LYMPHOMA PATIENTS WITH INADEQUATE RESPONSE TO CHEMOTHERAPY. THE PRELIMINARY EXPERIENCE FROM THE RAFTING TRIAL by Filonenko, K., Domingo‐Domenech, E., Gotti, M., Núñez, J., Rambaldi, A., Rodríguez, A., Tarella, C., Bednarek, M., Gallamini, A., Zaucha, J. M.

Get full text

Stable Mixed Hematopoietic Chimerism in Dog Leukocyte Antigen–Identical Littermate Dogs Given Lymph Node Irradiation Before and Pharmacologic Immunosuppression After Marrow Transplantation by Storb, Rainer, Yu, Cong, Barnett, Todd, Wagner, John L., Deeg, H. Joachim, Nash, Richard A., Kiem, Hans-Peter, McSweeney, Peter, Seidel, Kristy, Georges, George, Zaucha, J. Maciej

“…Stable mixed donor/host hematopoietic chimerism can be accomplished in dog leukocyte antigen (DLA)-identical littermate dogs given sublethal (200 cGy)…”
Get full text

International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20‐Positive B Cell PTLD: Clues From the PTLD‐1 Trial by Trappe, R. U., Choquet, S., Dierickx, D., Mollee, P., Zaucha, J. M., Dreyling, M. H., Dührsen, U., Tarella, C., Shpilberg, O., Sender, M., Salles, G., Morschhauser, F., Jaccard, A., Lamy, T., Reinke, P., Neuhaus, R., Lehmkuhl, H., Horst, H. A., Leithäuser, M., Schlattmann, P., Anagnostopoulos, I., Raphael, M., Riess, H., Leblond, V., Oertel, S.

“…Tailoring treatment by patient strata based on the risk of disease progression and treatment toxicity might improve outcomes of patients with posttransplant…”
Get full text

Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia by Hellmann, A., Lewandowski, K., Zaucha, J.M., Bieniaszewska, M., Hałaburda, K., Robak, T.

“…2‐Chlorodeoxyadenosine (2‐CdA) is a new purine analogue active in indolent lymphoid malignancies. In this retrospective study 22 patients with Waldenström's…”
Get full text

Baseline‐PET derived metrics are the most relevant factors for risk stratification in early‐stage nonbulky HL: preliminary results of the RAFTING trial by Zaucha, J. M., Picardi, M., Kurlapski, M., Patti, C., Domingo‐Domenech, E., Sanz, R. Garcia, Rossi, A., Lopez‐jimenez, J., Trentin, L., Gotti, M., Viviani, S., Sorasio, R., Giza, A., Martinez‐Munoz, C., Nunez‐Cespedes, J., Filonenko, K., Chauvie, S., Guerra, L., Rambaldi, A., Sureda, A., Gallamini, A.

Get full text

The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin’s lymphoma patients—the Polish Lymphoma Research Group (PLRG) Observational Study by Zaucha, J.M., Małkowski, B., Chauvie, S., Subocz, E., Tajer, J., Kulikowski, W., Fijołek-Warszewska, A., Biggi, A., Fallanca, F., Kobylecka, M., Dziuk, M., Woszczyk, D., Rybka, J., Kroll-Balcerzak, R., Bergesio, F., Romanowicz, A., Chamier-Ciemińska, A., Kurczab, P., Giza, A., Leśniewski-Kmak, K., Zaucha, R., Świetlik, D., Wróbel, T., Knopińska-Posłuszny, W., Walewski, J., Gallamini, A.

“…Interim PET after two ABVD cycles (iPET2) predicts treatment outcome in classical Hodgkin’s lymphoma. To test whether an earlier assessment of chemosensitivity…”
Get full text

AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL). REAL‐WORLD REPORT OF POLISH LYMPHOMA RESEARCH GROUP by Ostrowska, B., Domanska‐Czyz, K., Giza, A., Taszner, M., Romejko‐Jarosinska, J., Targonski, L., Poplawska, L., Konecki, R., Kotarska, M., Szymanski, M., Borawska, A., Swierkowska, M., Dabrowska‐Iwanicka, A., Druzd‐Sitek, A., Paszkiewicz‐Kozik, E., Mroz‐Zycinska, E., Osowiecki, M., Zimowska‐Curylo, D., Owczarek‐Kaczmarek, J., Tajer, J., Wojciechowska‐Lampka, E., Osiadacz, W., Rymkiewicz, G., Lapinska, G., Wojewodzka‐Mirocha, M., Rybski, S., Michalski, W., Krzanowski, J., Sacha, T., Zaucha, J. M., Walewski, J.

Get full text

RADIATION FREE THERAPY OR THE INITIAL TREATMENT OF GOOD PROGNOSIS EARLY NON‐BULKY HODGKIN LYMPHOMA, DEFINED BY A LOW METABOLIC TUMOR VOLUME AND A NEGATIVE PET‐2 ‐ RAFTING TRIAL by Gallamini, A., Walewski, J., Rambaldi, A., Viviani, S., Sureda, A., André, M., Rossi, C., Moccia, A., Zucca, E., Rossi, D., Filippi, A., Meignan, M., Chauvie, S., Zaucha, J. M.

Get full text

Clinical utility of circulating tumor DNA qualification and quantification in classical Hodgkin lymphoma by Pirosa, M. C., Bruscaggin, A., Terzi di Bergamo, L., Salehi, M., Spina, V., Pini, K., Bocchetta, S., Giordano, C., Forestieri, G., Condoluci, A., Piffaretti, D., Almeida, J. Marques, Galimberti, G. A., Annunziata, S., Bergesio, F., Boldorini, R., Borsatti, E., Bulian, P., Chauvie, S., Cuzzocrea, M., di Trani, M., Cristaldi, V., Gerber, B., Jauk, F., Kurlapski, M., Larocca, L. M., Moccia, A., Moia, R., Rinaldi, A., Rodari, M., Romanowicz, G., Sacchetti, G. M., Stathis, A., Stüssi, G., Zangrilli, I., Pinto, A., Mazzucchelli, L., Gattei, V., Zaucha, J. M., Hohaus, S., Santoro, A., Carlo‐Stella, C., Gaidano, G., Cavalli, F., Zucca, E., Ceriani, L., Rossi, D.

Get full text

PB2203: AGEING OF LONG‐TERM ALLOGENEIC HEMATOPOIETIC CELLS RECIPIENTS COMPARED TO THEIR DONORS by Czarnogórski, M., Sakowska, J., Maziewski, M., Zieliński, M., Witkowski, J. M., Piekarska, A., Obuchowski, I., Młyński, M., Trzonkowski, P., Dutka, M., Sadowska‐Klasa, A., Zarzycka, E., Bieniaszewska, M., Hellmann, A., Zaucha, J. M.

Get full text

CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC HODGKIN LYMPHOMA by Spina, V., Pirosa, M. C., Bruscaggin, A., Condoluci, A., Pini, K., Forestieri, G., Zangrilli, I., di Trani, M., Kurlapski, M., Moccia, A., Moia, R., Bulian, P., Annunziata, S., Borsatti, E., Rodari, M., Romanowicz, G., Sacchetti, G. M., Faderl, M., Koch, R., Piffaretti, D., Terzi di Bergamo, L., Stasia, A., Cittone, M., Chauvie, S., Stüssi, G., Gerber, B., Stathis, A., Sommer, S. Gillessen, Cavalli, F., Zucca, E., Gattei, V., Zaucha, J. M., Pinto, A., Gaidano, G., Carlo‐Stella, C., Hohaus, S., Ceriani, L., Rossi, D.

Get full text

S175: ATLAS: A PHASE 3 RANDOMIZED TRIAL OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE ALONE AFTER STEM‐CELL TRANSPLANT FOR MULTIPLE MYELOMA by Dytfeld, D., Wróbel, T., Jamroziak, K., Kubicki, T., Robak, P., Walter‐Croneck, A., Czyż, J., Tyczyńska, A., Druzd‐Sitek, A., Giannopoulos, K., Nowicki, A., Szczepaniak, T., Łojko‐Dankowska, A., Matuszak, M., Gil, L., Puła, B., Rybka, J., Majcherek, M., Usnarska‐Zubkiewicz, L., Szukalski, L., Końska, A., Zaucha, J. M., Walewski, J., Mikulski, D., Czabak, O., Robak, T., Grzybowska, U., Lahoud, O. B., Zonder, J. A., Griffith, K., Stefka, A., Major, A., Derman, B. A., Jakubowiak, A. J.

Get full text

Imatinib‐associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia by ZAUCHA, J. M., WYROWINSKA, E., PREJZNER, W., CALBECKA, M., HELLMANN, A.

“…Summary Imatinib mesylate is a very effective treatment in patients with Philadelphia (Ph)‐positive chronic myeloid leukaemia (CML). However, in patients with…”
Get full text

S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMA by Pirosa, M. C., Bruscaggin, A., Terzi di Bergamo, L., Salehi, M., Pini, K., Spina, V., Bocchetta, S., Condoluci, A., Forestieri, G., Piffaretti, D., Marques De Almeida, J., Annunziata, S., Bergesio, F., Borsatti, E., Bulian, P., Chauvie, S., Marco, C., Martina, D. T., Bernhard, G., Kurlapski, M., Moccia, A., Moia, R., Rinaldi, A., Rodari, M., Romanowicz, G., Sacchetti, G. M., Stasia, A., Stathis, A., Stüssi, G., Zangrilli, I., Larocca, L. M., Pinto, A., Santoro, A., Cavalli, F., Zucca, E., Gattei, V., Zaucha, J. M., Carlo‐Stella, C., Hohaus, S., Gaidano, G., Ceriani, L., Rossi, D.

Get full text

Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients—Report of the Polish Myeloma Group by Usnarska-Zubkiewicz, L, Dębski, J, Butrym, A, Legieć, W, Hus, M, Dmoszyńska, A, Stella-Hołowiecka, B, Zaucha, J.M, Januszczyk, J, Rymko, M, Torosian, T, Charliński, G, Lech-Marańda, E, Malenda, A, Jurczyszyn, A, Urbańska-Ryś, H, Druzd-Sitek, A, Błońska, D, Urbanowicz, A, Hołojda, J, Pogrzeba, J, Rzepecki, P, Hałka, J, Subocz, E, Becht, R, Zdziarska, B, Dytfeld, D, Nowicki, A, Bołkun, Ł, Kłoczko, J, Knopińska-Posłuszny, W, Zubkiewicz-Kucharska, A, Kuliczkowski, K

“…Highlights • Lenalidomide is an effective treatment in RRMM. • ORR increased, reaching 51%, 64% and 68% after 2, 4 and 6 cycles of LEN. • Lenalidomide showed…”
Get full text